Suzhou Ribo Life Science Co., Ltd. (HKG:6938)

Market Cap	11.95B
Revenue (ttm)	197.39M +324,052.3%
Net Income	-241.87M
EPS	-1.87
Shares Out	170.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	201,000
Average Volume	545,223
Open	74.05
Previous Close	74.05
Day's Range	69.05 - 74.55
52-Week Range	58.55 - 95.80
Beta	n/a
RSI	42.95
Earnings Date	n/a

About Suzhou Ribo Life Science

Suzhou Ribo Life Science Co., Ltd. researches and develops small nucleic acid drugs for treating cardiovascular, metabolic, renal, liver, and other diseases. It develops RBD4059 for treating thrombotic diseases; RBD5044 for treating hypertrigly ceridemia; RBD7022 for treating Hypercho lesterolemia; RBD1016 for treating CHB and CHD that are in Phase II clinical trials. The company also develops RBD7007 and RBD2080 for treating renal diseases; and RBD1119 for treating thrombotic diseases, which are in Phase I clinical trials. In addition, it deve...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 404
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6938

Financial Performance

In 2024, Suzhou Ribo Life Science's revenue was 142.63 million, an increase of 324052.27% compared to the previous year's 44,000. Losses were -270.15 million, -36.93% less than in 2023.

Financial numbers in CNY